Payment overview · 2025
General Payments
$34.23
2 reported records · 2 companies
Healthcare provider profile · identity verified
Richard Dube, MD
Allopathic & Osteopathic Physicians|Family Medicine · STUART, FL · NPI 1356360606
Verified facts
What the public records show
CMS Open Payments records show Richard Dube, MD received $34.23 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 52.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.88 | 52.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.35 | 47.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $34.23 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
110 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 605 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 142 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 464 | 141 |
| Alprazolam | Alprazolam | 442 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 422 | 123 |
| Losartan Potassium | Losartan Potassium | 388 | 117 |
| Ezetimibe | Ezetimibe | 326 | 86 |
| Furosemide | Furosemide | 322 | 94 |
| Lorazepam | Lorazepam | 309 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 93 |
| Lisinopril | Lisinopril | 274 | 76 |
| Omeprazole | Omeprazole | 266 | 81 |
| Simvastatin | Simvastatin | 261 | 65 |
| Gabapentin | Gabapentin | 240 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 68 |
| Metformin Hcl | Metformin Hcl | 206 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 201 | 48 |
| Bupropion Hcl Sr | Bupropion Hcl | 184 | 47 |
| Azithromycin | Azithromycin | 167 | 109 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 47 |
| Oxycodone Hcl | Oxycodone Hcl | 157 | 18 |
| Atenolol | Atenolol | 137 | 35 |
| Prednisone | Prednisone | 135 | 81 |
| Potassium Chloride | Potassium Chloride | 134 | 36 |
| Allopurinol | Allopurinol | 128 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 21 |
| Tramadol Hcl | Tramadol Hcl | 127 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 31 |
| Ozempic | Semaglutide | 111 | 22 |
| Sertraline Hcl | Sertraline Hcl | 111 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 30 |
| Montelukast Sodium | Montelukast Sodium | 110 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 21 |
| Famotidine | Famotidine | 108 | 33 |
| Mounjaro | Tirzepatide | 105 | 19 |
| Trazodone Hcl | Trazodone Hcl | 103 | 27 |
| Spironolactone | Spironolactone | 101 | 26 |
| Temazepam | Temazepam | 99 | 17 |
| Eliquis | Apixaban | 92 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 27 |
| Trulicity | Dulaglutide | 88 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 65 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 24 |
| Diazepam | Diazepam | 78 | 21 |
| Meloxicam | Meloxicam | 77 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 75 | 56 |
| Clonazepam | Clonazepam | 75 | 18 |
| Finasteride | Finasteride | 69 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 19 |
| Synthroid | Levothyroxine Sodium | 68 | 20 |
| Propranolol Hcl | Propranolol Hcl | 67 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 66 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 20 |
| Carvedilol | Carvedilol | 60 | 16 |
| Valsartan | Valsartan | 60 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 50 |
| Amoxicillin | Amoxicillin | 57 | 37 |
| Metformin Hcl Er | Metformin Hcl | 57 | 21 |
| Baclofen | Baclofen | 56 | 11 |
| Glimepiride | Glimepiride | 55 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 50 |
| Valacyclovir | Valacyclovir Hcl | 49 | 23 |
| Donepezil Hcl | Donepezil Hcl | 48 | 17 |
| Fenofibrate | Fenofibrate | 48 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 48 | 15 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 41 | 31 |
| Mupirocin | Mupirocin | 37 | 28 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Folic Acid | Folic Acid | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 24 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lactulose | Lactulose | 20 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Qulipta | Atogepant | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34.23 · 2 records | Novo Nordisk Inc | AREXVY, SHINGRIX, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error